AstraZeneca PLC · LSE:AZN
AstraZeneca — Technical Presentation (1999)
16 slides from AstraZeneca's technical presentation, 1999
Slide 1: AstraZeneca CNS: The CNS opportunity
AstraZeneca CNS Ron Polinsky Vice President CNS TA The CNS opportunity h Devastating disability h Immense cost burden h Huge unmet medical need h “Decade of the Brain” h Fastest growing segment
Slide 2: Major market potential in psychiatry & neurology
Major market potential in psychiatry & neurology 1998 Estimated 2010 $19bn Psycho- $50bn Psycho- Neurological Neurological therapeutics therapeutics AstraZeneca - broad coverage in CNS Strategic Targets CNS Therapeutic Brands on the Market Area Compounds in Development Neurology Psychiatry Acute Str
Slide 3: Migraine: Zomig outselling naratriptan/rizatriptan
Migraine h Disabling disease h Common (up to 15%) h Attacks are unpredictable h Migraine sufferers need rapid, reliable, consistent relief … any time Zomig® outselling naratriptan/rizatriptan 120 Zomig® naratriptan rizatriptan 100 80 60 $m 40 20 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 97 97 97 98 98 98 98 99 9
Slide 4: Zomig - effective management of migraine
Zomig® - effective management of migraine AstraZeneca is investing globally in MIDAS (Migraine Disability Assessment) h Helps physicians improve migraine care h Simple, clinically validated questionnaire h Relates illness severity to treatment needs h DISC (Disability In Stratified Care) Study - sho
Slide 5: Zomig Rapimelt
Zomig® Rapimelt™ h Convenient melt formulation h No water needed h Pleasant orange flavour Zomig® Rapimelt™ Slide unpublished
Slide 6: Zomig Rapimelt - regulatory status
Zomig® Rapimelt™ - regulatory status h Confirmation of EU mutual recognition approval for Zomig® Rapimelt™ - Sweden (reference member state for mutual recognition) - Germany - Greece - Austria - Italy - Belgium - Spain - Denmark - Finland - Luxembourg - Portugal h National approval in Ireland h Firs
Slide 7: Schizophrenia: Seroquel - significant efficacy
Schizophrenia h Chronic disease - “the cancer of mental illnesses” h Severe “positive” and “negative” symptoms h High suicide rate h Typical therapies - severe side effects h Market growing at 28% p.a. Seroquel® - significant efficacy EPS adverse event Efficacy responders ≥ 40% reduction from baseli
Slide 8: Seroquel - no EPS at any dose
Seroquel® - no EPS at any dose 50 p<0.05 40 vs placebo Need for anticholinergic 30 medication (% patients) 20 10 0 Placebo 75 150 300 600 750 haloperidol ® 12 mg/day Seroquel (mg/day) Arvanitis et al 1997 Seroquel® - no EPS at any dose EPS 5 times more likely with risperidone (p<0.001) 25 20 % patie
Slide 9: Seroquel - minimal weight gain and regulatory situation
Seroquel® - minimal weight gain Seroquel® olanzapine 8 8 Change from baseline 6 6 weight (kg) 4 4 2 2 0 0 5-6 24-36 36-52 0 4 8 12 16 20 24 28 32 36 40 44 48 52 Time (weeks) Time (weeks) AstraZeneca, data on file Kinon et al Seroquel® - regulatory situation h Approved in 45 countries (including US,
Slide 10: Seroquel - development programmes
Seroquel® - development programmes h New indications – mania – Alzheimer’s disease h New presentations – starter packs – sustained release – granules Seroquel® - sustained release Concentration-time profiles of Seroquel® IR and Seroquel® SR tablets in patients Study 5077IL/0037 600 Concentration (ng
Slide 11: Seroquel planned regulatory submissions; Acute ischemic stroke
Seroquel® planned regulatory submissions Mania (EU) 150 mg tablet Mania (US) 1999 2000 2001 2002 300 mg tablet Granules Sustained release Alzheimer’s (US) Ongoing clinical evaluation programme Acute ischemic stroke h Third leading cause of death h Most common cause of disability h Up to 10% of US he
Slide 12: Acute stroke portfolio
Acute stroke portfolio h Zendra® Phase III – enhances GABAA receptor activity h NXY 059* Phase II – free radical trapping agent h AR-R15896AR Phase II – low affinity, use dependant NMDA antagonist AstraZeneca has an industry-leading portfolio * AstraZeneca is developing NXY-059 under a license agree
Slide 13: Zendra - functional independence
Zendra® - functional independence Barthel Index at 90 days (primary endpoint, % > 60) TACS 28.6% 32.2% deaths 30.7% 38.0% 0–55 40.8% 29.8% 60–100 Absolute difference 11 Zendra® Placebo Relative difference 37% n=287 n=258 Zendra® - phase III h Stroke victims with the greatest need (large ischemic str
Slide 14: Remacemide - novel approach
Remacemide - novel approach h Low affinity NMDA channel blocker h Parkinson’s disease - phase II h Huntington’s disease - phase III (NIH) h Epilepsy - phase III h Potential in neuroprotection Depression Several approaches h NAD 299 (5HT1a antagonist) h AR-A000002 (5HT1b antagonist) h ZD4974 (NK1 ant
Slide 15: NK1 antagonists; CNS planned regulatory submissions
NK1 antagonists A new mechanistic approach to anxiety/depression Goal - once a day oral treatment for anxiety/depression and associated CNS disorders 100 Compound A: provides long- acting protection from stress % protection 75 50 25 Example from 0 pre-clinical collection 6 7 8 10 14 18 24 Hours afte
Slide 16: Slide 16